Chamber and committees

The information requested is not held centrally by the Scottish Government.

I refer the member to the answer to question S6W-21589 on 5 October 2023, which contains data from Public Health Scotland on the number of inpatient and day case admissions to hospital where a diagnosis of dog attack (bite or strike) was recorded, from 2010 to 2022, in Scotland. Public Health Scotland do not collect that data broken down by dog breed type.

All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

From May 2022, Health Boards are responsible for providing Community Treatment and Care (CTAC) services, including ear wax removal, to support GPs to do the job they are trained to do and to give patients access to a wider range of expert advice for their care. While we have made good progress in implementing CTAC and other multidisciplinary team (MDT) services, we know that service gaps remain.

We are therefore introducing an additional phased investment programme over the next 18 months, working with a small number of areas, at different stages of implementation, to demonstrate what a model of full implementation of CTAC, as well as pharmacotherapy services, can look like in practice. The evidence obtained through this programme will then inform a long-term investment proposition for these services.

We will also ensure that content on NHS inform is underpinned as far as possible with current clinical evidence.

As at 28 September 2023, no whole organs (including brains) are being retained following a post mortem examination instructed by the Procurator Fiscal.

Human tissue samples are obtained in the majority of post mortem examinations instructed by the Procurator Fiscal, but only where necessary to assist in confirming the deceased’s cause of death, identify inherited genetic conditions or to establish identification through DNA.

It is a matter for the pathologist conducting the post mortem examination to decide whether it is necessary to obtain tissue samples in order for them to instruct further tests or examinations to clarify the cause of death. The pathologist will make the decision whether any organs require to be removed during the examination for further testing, either whole organs, or small samples from organs. At the conclusion of the Procurator Fiscal’s investigation, by virtue of the Human Tissue (Scotland) Act 2006 any blocks and slides prepared for the purposes of histopathology (examination of the tissue under a microscope to detect any signs of disease, damage or other abnormalities) are considered to be part of the medical records of the deceased person. No samples that are retained are kept by COPFS and they are instead retained by the NHS.

COPFS keeps a record of all cases where a pathologist has decided that it is necessary to retain a whole organ during a post mortem examination. This record also includes details of when an organ is returned to the family of the deceased at the conclusion of examinations.

It is not possible to provide an exact figure of the number of other samples currently being retained.

Scottish Government guidance is reviewed and updated regularly to ensure that information for the public and organisations/businesses aligns to current policy.

The Scottish Government Marketing Resource Centre is the central repository for stakeholder resources which reflect that no Covid restrictions are now in place. Material for the Stay Well campaign is available via the resource centre from stakeholder toolkits. Any out-of-date resources are removed from circulation. If a stakeholder was to visit the resource centre for relevant materials, they would only have access to valid guidance.

The Scottish Government defines a “Just Transition” as both an outcome – a fairer, greener future for all – and the process that must be undertaken in partnership with those impacted by the transition.

The Agriculture Bill recognises the importance of both this outcome and approach.

The Scottish Government is committed to its obligations under the Article 5.3 of the WHO Framework Convention on Tobacco Control.

In line with the WHO Guidelines for implementation, the Scottish Government Tobacco Control Team is undertaking a number of measures to support compliance. This includes, but is not limited to:

• Continuing to raise awareness of Article 5.3 across Scottish Government, Local Government and related bodies.
• Asking consultation respondents to make a declaration of any links to the Tobacco Industry within tobacco and vaping consultations, including the 2022 consultation on tightening rules on advertising and promotion of vaping products. and the recent 4-nations consultation on mandating quit information messages inside tobacco packs.
• Sharing UK Government guidance on engagement with the tobacco industry with internal and external stakeholders.

Further information on implementation of Article 5.3 will be included in our refreshed Tobacco Action Plan which will publish later in autumn.

Work is already underway to create a new payment structure, and as with the current one, which has seen 2023 Basic payments begin at the earliest point ever in September year in a row, our intention is for the future structure and system to make payments in a timely manner.

In line with normal processes, transfers of budget, including those to the Scottish Police Authority, will be communicated to Parliament through the Autumn and Spring Budget Revisions.

In Scotland, the Scottish Medicines Consortium (SMC) appraises the clinical and cost-effectiveness of newly licensed medicines. Following a full submission for rimegepant (Vydura ® ) for the acute treatment of migraine with or without aura in adults, the SMC issued ‘accepted for restricted use’ advice for routine use of this medicine in NHS Scotland on 9 May 2023.

The SMC restriction is that the use of this medicine should be restricted to patients who have had inadequate symptom relief after trials of at least two triptans (a group of medicines used to treat migraine or headache), or in whom triptans are contraindicated or not tolerated; and have inadequate pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. Final draft guidance on routine use of this medicine in NHS England issued by the National Institute for Health and Care Excellence (NICE) is similar to that issued for Scotland.

We understand the distress and pain that migraines cause and want to ensure that everyone living with this debilitating condition can access the best possible care and support.

The Scottish Government awarded a further £135,501 to the Migraine Trust in October 2023 through our Neurological Care and Support: Framework for Action for 2023-2024 towards their work with pharmacists in NHS Grampian to help people manage their symptoms and treatments more effectively.